AVOID试验:HPV相关口咽癌TORS术后省略原发瘤床放疗的2期研究
该单臂2期前瞻性试验纳入60例pT1-pT2 N1-3 HPV相关口咽鳞癌患者,TORS及选择性颈清扫后,术后放疗避让原发瘤床、仅照射危险颈部区域(受累颈60-66 Gy,未受累颈54 Gy),中位随访2.4年,2年局部控制率98.3%,总生存100%,原发灶平均剂量36.9 Gy,结论提示该降强度策略可能安全且值得进一步研究。
要点
- TORS术后避让原发瘤床、仅照射危险颈部,2年局部控制率98.3%。
- 原发灶平均放疗剂量36.9 Gy(标准差10.3 Gy),总生存100%。
- 随访期间暂时性胃管依赖率3.3%,末次随访为0%。
核心结论
- 对经选择的HPV相关口咽鳞癌患者,TORS术后避让原发瘤床、仅照射危险颈部的降强度术后放疗可能安全,值得进一步研究。
研究设计与样本
- 单臂2期前瞻性临床试验,2014年5月至2017年9月单中心纳入60例pT1-pT2 N1-3 HPV相关口咽鳞癌患者,均行TORS及选择性颈清扫。
主要发现
- 中位随访2.4年(范围8.5-53.8个月),1例原发部位复发,2年局部控制率98.3%。
- 1例(1.7%)出现颈部区域复发,2例(3.3%)出现远处转移。
- 2年局部无复发生存率97.9%(95%CI 86.1%-99.7%),分析时总生存率100%。
- 原发灶平均放疗剂量36.9 Gy(标准差10.3 Gy)。
- 2例(3.3%)出现原发灶手术床晚期软组织坏死,均在2个月内消退;胃管依赖率放疗期间0%、随访期间暂时性3.3%、末次随访0%。
关键数值与推荐
- 入组原发灶需具备有利特征:手术切缘阴性≥2 mm、无神经侵犯、无淋巴血管侵犯,但因淋巴结受累需辅助治疗。
- 术后放疗剂量:受累颈部危险区60-66 Gy,未受累颈部54 Gy;原发灶手术床作为主动避让结构。
- 有结外扩展者接受同步化疗。
临床怎么用
- 对经选择的HPV相关口咽鳞癌TORS术后患者,可考虑避让原发瘤床、仅照射危险颈部的降强度放疗策略。
- 该策略需在多学科评估原发灶有利病理特征后实施,并注意晚期软组织坏死等不良反应。
局限性
- 单臂2期研究,单中心、样本量60例,中位随访仅2.4年。
- 手术均在具备TORS专长的高容量头颈肿瘤中心完成,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This trial tested the safety and efficacy of a novel, deintensified radiation therapy (RT) approach after initial surgical resection for patients with human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). METHODS AND MATERIALS: This single-arm phase 2 prospective clinical trial enrolled 60 patients with stage pT1-pT2 N1-3 HPV-associated OPSCC treated with transoral robotic surgery (TORS) and selective neck dissection at a single institution between May 2014 and September 2017. Patients had favorable features at the primary site (negative surgical margins ≥2 mm, no perineural invasion, and no lymphovascular invasion) but required adjuvant therapy based on lymph node involvement. Surgeries were all performed at a high-volume head and neck cancer center with expertise in TORS. Patients received postoperative RT to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy). The resected primary site was treated as an active avoidance structure in the treatment planning of postoperative RT. Concurrent chemotherapy was administered for patients with extranodal extension. RESULTS: Median follow-up of the 60 patients enrolled was 2.4 years (range, 8.5-53.8 months). A single patient recurred at the primary site, for 2-year local control of 98.3%. One patient (1.7%) developed a regional neck recurrence, and 2 patients (3.3%) developed distant metastases. Measured 2-year local recurrence-free survival was 97.9% (95% confidence interval, 86.1%-99.7%). Overall survival was 100% at the time of analysis. The mean radiation dose to the primary site was 36.9 Gy (standard deviation, 10.3 Gy). Two patients (3.3%) experienced late soft tissue necrosis in the primary site surgical bed that resolved within 2 months. Feeding tube dependence rates were 0% during RT, 3.3% temporarily during follow-up, and 0% at last follow-up. CONCLUSIONS: Deintensified postoperative RT that avoids the resected primary tumor site and targets only the at-risk neck after TORS for selected patients with HPV-associated OPSCC may be safe and is worthy of further study.
引用
- Swisher-McClure S, Lukens JN, Aggarwal C, et al. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx. Int J Radiat Oncol Biol Phys. 2019. PMID: 31785337. doi:10.1016/j.ijrobp.2019.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。